Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A KEITH

Showing results (871-880 of 918) with videos related to

Pageof 92
Sort By:
Blood Cancer Journal|August 1, 2018
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myelomaShaji K Kumar, Francis K Buadi, Betsy LaPlant, et al.
Mayo Clinic Proceedings|December 4, 2009
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesShaji K Kumar, Joseph R Mikhael, Francis K Buadi, et al.
Blood|January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportAntonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
Leukemia|October 14, 2024
Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14)Hongwei Tang, Huihuang Yan, Suganti Shivaram, et al.
Blood Cancer Journal|May 13, 2020
"Direct to Drug" screening as a precision medicine tool in multiple myelomaCecilia Bonolo de Campos, Nathalie Meurice, Joachim L Petit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpThomas Martin, Saad Z Usmani, Jesus G Berdeja, et al.
Mayo Clinic Proceedings|August 12, 2006
Mayo clinic consensus statement for the use of bisphosphonates in multiple myelomaMartha Q Lacy, Angela Dispenzieri, Morie A Gertz, et al.
Proceedings. Biological Sciences|April 21, 2021
A deepening understanding of animal culture suggests lessons for conservationPhilippa Brakes, Emma L Carroll, Sasha R X Dall, et al.
Cancer Cell|August 19, 2007
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myelomaJonathan J Keats, Rafael Fonseca, Marta Chesi, et al.
Plos One|October 17, 2012
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencingWinnie S Liang, David W Craig, John Carpten, et al.
Pageof 92

Showing results (871-880 of 918) with videos related to

Sort By:
Pageof 92
Blood Cancer Journal|August 1, 2018
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myelomaShaji K Kumar, Francis K Buadi, Betsy LaPlant, et al.
Mayo Clinic Proceedings|December 4, 2009
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesShaji K Kumar, Joseph R Mikhael, Francis K Buadi, et al.
Blood|January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportAntonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
Leukemia|October 14, 2024
Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14)Hongwei Tang, Huihuang Yan, Suganti Shivaram, et al.
Blood Cancer Journal|May 13, 2020
"Direct to Drug" screening as a precision medicine tool in multiple myelomaCecilia Bonolo de Campos, Nathalie Meurice, Joachim L Petit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpThomas Martin, Saad Z Usmani, Jesus G Berdeja, et al.
Mayo Clinic Proceedings|August 12, 2006
Mayo clinic consensus statement for the use of bisphosphonates in multiple myelomaMartha Q Lacy, Angela Dispenzieri, Morie A Gertz, et al.
Proceedings. Biological Sciences|April 21, 2021
A deepening understanding of animal culture suggests lessons for conservationPhilippa Brakes, Emma L Carroll, Sasha R X Dall, et al.
Cancer Cell|August 19, 2007
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myelomaJonathan J Keats, Rafael Fonseca, Marta Chesi, et al.
Plos One|October 17, 2012
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencingWinnie S Liang, David W Craig, John Carpten, et al.
Pageof 92